FinscoFinsco

Biogen (US.BIIB)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.BIIB · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion79.2%→
ROE2.2%↓
Cash Conversion262.4%↑
D/E Ratio0.44↓
Gross Margin72.4%→
US.BIIB (Biogen) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion    79.2%    →
ROE                2.2%    ↓
Cash Conversion  262.4%    ↑
D/E Ratio          0.44    ↓
Gross Margin      72.4%    →
Key Metrics
US.BIIB (Biogen) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 79.2% →
ROE 2.2% ↓
Cash Conversion 262.4% ↑
D/E Ratio 0.44 ↓
Gross Margin 72.4% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies